RTSN

10.51019.22%
MJ

Michael Joseph Berendt

Executive Chairman

Dr. Michael Joseph Berendt, also known as Mike,Ph.D, is Chairman of Response Pharmaceuticals INC. Dr. Berendt is Executive Chairman of Retension Pharmaceuticals, Inc. from July 2023. Dr. Berendt was Director of Retension Pharmaceuticals, Inc. Dr. Berendt has been the Chief Executive Officer of Telesta Therapeutics Inc. since November 4, 2013 and has been its Chief Scientist Officer since November 4, 2013. Dr. Berendt served as the Chief Executive Officer and President of Aegera Therapeutics Inc. since January 14, 2007 until 2011. Dr. Berendt served as the Managing Director of AEA Investors LP. He served as a Consultant of Bioniche Life Sciences Inc. From November 2000 to August 2004, he served as the Managing Director of Life Sciences Group, AEA Investors Inc. Prior to Aegera, from August 2004 to March 2006, he served as the Managing Director of the Atlantic Region of Research Corporation Technologies Inc.(RCT), a technology investment and management company which he joined after establishing a life sciences investment team focused on growth equity investments for AEA Investors Inc. since November 2000. Prior to AEA, he served as the Senior Vice President of Research for the Pharmaceutical Division at Bayer Corp. from November 1996 to November 2000 and served in the same role with its subsidiary Bayer Pharmaceuticals Corporation. From January 1996 to November 1996, he served as the Vice President of Institute of Bone & Joint Disorders and Cancer, Bayer Corp., Pharmaceutical Division. From October 1993 to January 1996, he served as the Director of Institute for Bone & Joint Disorders and Cancer, Bayer Corp., Pharmaceutical Division. Prior to Bayer, Dr. Berendt served as Group Director of Drug Discovery of Pfizer Inc. and was responsible for immunology pulmonary, inflammation and antibiotic research. He served as an Interim Chairman of Alethia BioTherapeutics, Inc. until January 9, 2017. He serves as a Director of Anchor Therapeutics, Inc. and Trillium Therapeutics Inc. He served as an Independent Director of Waters Corporation since March 1998 until October 05, 2021 and serves as an Independent Director of Waters Technologies Corporation since March 1998. He has been a Director of Telesta Therapeutics Inc. since November 5, 2013. He serves as a Director of Bioniche Animal Health USA, Inc. and The NEOMED Institute. He served as a Director of Alethia BioTherapeutics, Inc. until January 9, 2017. He served as a Director of Aegera Therapeutics, Inc. He served as a Director of Catalyst Biosciences, Inc., Onyx Pharmaceuticals Inc., Myriad Genetics Inc. and Northstar Neuroscience Inc. He served as a Director of Nanostream Inc. He served as a Director of Intronn Inc., Vertis Neuroscience Inc. He served as a Director of Nobex Corporation. He was awarded a research fellowship from the National Cancer Institute, Leukemia Society of America and American Cancer Society. Dr. Berendt is a graduate of Ohio Dominican College, has an M.S. in Microbiology from Miami University and PhD in Medical Microbiology and Immunology from Hahnemann Medical College (now Drexel University).

Positions